Answers are grounded in this paper and cite their sources.
With interest we read the case reports on lactic acidosis by Johri et al. [1]. Several parts of their paper can be disputed, such as the improbable shortness of nucleoside reverse transcriptase inhibitor (NRTI) treatment of patient 2 (1 month?) before the development of fatal lactic acidosis. In particular, the discussion on treatment elicits a reaction. The authors assume that their first patient possibly survived as a result of combined treatment with co-enzyme Q, carnitine and vitamin C. They use the report of Lenzo et al. [2] to support the role of co-enzyme Q in this respect. The latter report was not written to demonstrate a possible role for this co-factor in the treatment of lactic acidosis, but was the first in a series on the role of stavudine in this syndrome. Although co-enzyme Q is an important co-factor in oxidative phosphorylation, its role in the treatment of mitochondrial dysfunction was never clearly demonstrated, despite several (small) studies [3,4]. The same arguments hold for vitamin C and carnitine therapy, although a recent case report advocates some benefit from the latter in a case of NRTI-induced lactic acidosis [5]. Unfortunately, Johri et al. [1] gave no details about the dosages of treatment of any of their compounds, about whether these treatments were given orally or parenterally or about the duration of treatment. This is unfortunate, because a substance like co-enzyme Q is not a registered pharmaceutical drug in our country and is therefore not available for parenteral administration. With reports such as those discussed above, the treatment of NRTI-induced lactic acidosis will remain obscure and accidental. So far, only three case reports in the literature have given some more detailed information on therapies for NRTI-related lactic acidosis, in which success for these interventions is claimed: 50 mg riboflavin [6,7] or 50 mg/kg l-carnithine [5]. In the above reports, no information was given on the method of administration or the duration of treatment. Furthermore, the authors did not give any rationale for the dosages used, and as no studies have ever been performed to determine the optimal dosages for any of these treatments for mitochondrial diseases, one has to assume that these dosages were chosen randomly. As it seems unlikely that randomized or dose-determining studies will ever give the answers, we devised a treatment protocol for use in our country, based on the scarce data as discussed above. In cases of NRTI-induced lactic acidosis (serum lactate ≥ 5 mmol/l and serum bicarbonate ≤ 20 mmol/l) we interrupt the NRTI treatment immediately, ensure adequate blood pressure with intravenous fluid and start treatment with vitamin B complex forte (per 2 ml ampoule: 50 mg thiamine, 10 mg riboflavin, 100 mg nicotinamide, 10 mg pyridoxine, 10 mg dexpanthenol) 4 ml twice a day and l-carnitine 1000 mg twice a day, both given intravenously. We continue this treatment until lactate levels fall below 3 mmol/l, after which oral administration might be considered. Since November 1999, six patients have been treated with this treatment protocol and all survived (Table 1). Although this successful outcome might have resulted from an increased awareness of this syndrome, the positive effect of either of the co-factors alone or their combination cannot be ruled out. Because the generally reported outcome of this syndrome had mortality rates of over 50%, the successful outcome in our patients encourages us to continue our approach. In the future, only those reports giving more detailed information will provide a better insight into treatment strategies for NRTI-induced lactic acidosis.
No takes yet. Share an insight, caveat, or question.
Brinkman et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: